Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) Research & Development: 2023-2025

Historic Research & Development for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $34.4 million.

  • Zenas BioPharma's Research & Development rose 2.60% to $34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.5 million, marking a year-over-year increase of 46.29%. This contributed to the annual value of $139.1 million for FY2024, which is 131.77% up from last year.
  • As of Q3 2025, Zenas BioPharma's Research & Development stood at $34.4 million, which was down 20.05% from $43.0 million recorded in Q2 2025.
  • Zenas BioPharma's Research & Development's 5-year high stood at $49.2 million during Q4 2024, with a 5-year trough of $9.4 million in Q3 2023.
  • Its 3-year average for Research & Development is $31.3 million, with a median of $33.8 million in 2024.
  • Data for Zenas BioPharma's Research & Development shows a peak YoY skyrocketed of 258.53% (in 2024) over the last 5 years.
  • Zenas BioPharma's Research & Development (Quarterly) stood at $20.4 million in 2023, then surged by 140.75% to $49.2 million in 2024, then climbed by 2.60% to $34.4 million in 2025.
  • Its Research & Development stands at $34.4 million for Q3 2025, versus $43.0 million for Q2 2025 and $34.9 million for Q1 2025.